Celldex Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview

Celldex Therapeutics

23/02/2024 11:15

* Celldex Therapeutics Inc  CLDX.OQ   CLDX.O  is expected
to show
a fall in quarterly revenue when it reports  results on February
26 (estimated) for the period ending December 31 2023
    * The Hampton New Jersey-based  company is expected to
report a
47.7% decrease in revenue to $842.86 thousand from $1.61 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Celldex Therapeutics Inc
is
for a loss of 74 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Celldex
Therapeutics Inc is $65.00​, above​ its last closing price
of $37.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.68       -0.68      -0.81     Missed  -19.4
 Jun. 30 2023  -0.67       -0.67      -0.65     Beat    2.5
 Mar. 31 2023  -0.63       -0.63      -0.62     Beat    1.9​
 Dec. 31 2022  -0.59       -0.59      -0.56     Beat    5.1
 ​​Sep.        -0.57       -0.58      -0.57     Beat    1.2
 30 2022                                                
 Jun. 30 2022  -0.51       -0.51      -0.59     Missed  -15.7​
 Mar. 31 2022  -0.45       -0.45      -0.49     Missed  -7.9
 Dec. 31 2021  -0.42       -0.42      -0.43     Missed  -3.2
 This summary was machine generated February 23 at 11:15 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)